Clinical Trial Update: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 study of PM01183 (lurbinectedin) in patients with acute leukemia and relapsed/refractory myelodysplastic syndrome has completed enrollment and status up…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: PharmaMar | Conditions: Acute Leukemia | Phase 1 | Status: COMPLETED